EZH2 and melanoma: Treatment of these cells with different doses of the chemotherapy drugs (BRAF inhibitor), dabrafenib or vemurafenib (61), used in melanoma treatment revealed that USP7- or EZH2-deficient cells were more sensitive to chemotherapeutics, which could be partially rescued by FOXO1 knockdown (Figure 7D).